These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25275295)

  • 1. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions.
    Sakai K; Kazama S; Nagai Y; Murono K; Tanaka T; Ishihara S; Sunami E; Tomida S; Nishio K; Watanabe T
    Oncotarget; 2014 Oct; 5(20):9641-9. PubMed ID: 25275295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Qian C; Yang W; Li M; Feng Y; Dai N; Luo H; Jian D; Li X; Yang Y; He Y; Wang D; Li C; Xiao H
    Eur J Surg Oncol; 2024 Apr; 50(4):108242. PubMed ID: 38460248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
    Kim SY; Baek JY; Oh JH; Park SC; Sohn DK; Kim MJ; Chang HJ; Kong SY; Kim DY
    Radiat Oncol; 2017 Mar; 12(1):62. PubMed ID: 28347333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer.
    Ishihara S; Hayama T; Yamada H; Nozawa K; Matsuda K; Watanabe T
    Hepatogastroenterology; 2011; 58(107-108):756-62. PubMed ID: 21830385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
    Wang LW; Hsiao CF; Chen WT; Lee HH; Lin TC; Chen HC; Chen HH; Chien CR; Lin TY; Liu TW
    J Surg Oncol; 2014 May; 109(6):580-5. PubMed ID: 24374744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rectal cancer sub-clones respond differentially to neoadjuvant therapy.
    Frydrych LM; Ulintz P; Bankhead A; Sifuentes C; Greenson J; Maguire L; Irwin R; Fearon ER; Hardiman KM
    Neoplasia; 2019 Oct; 21(10):1051-1062. PubMed ID: 31521947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Miyakita H; Ogimi T; Nagase H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1077-1085. PubMed ID: 28417167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.
    Nakagawa R; Inoue Y; Ohki T; Kaneko Y; Maeda F; Yamamoto M
    World J Surg Oncol; 2017 May; 15(1):112. PubMed ID: 28566093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
    Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
    Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
    Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
    J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.
    Huang MY; Lin CH; Huang CM; Tsai HL; Huang CW; Yeh YS; Chai CY; Wang JY
    World J Surg; 2015 May; 39(5):1257-67. PubMed ID: 25561186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Poor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer Using a DNA Repair Deregulation Score: Picking the Losers Instead of the Winners.
    Jimenez L; Perez RO; São Julião GP; Vailati BB; Fernandez LM; Gama-Rodrigues J; Habr-Gama A; DeVecchio J; Kalady MF; Camargo AA
    Dis Colon Rectum; 2020 Mar; 63(3):300-309. PubMed ID: 31842156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
    Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
    Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy.
    Yamamoto A; Toiyama Y; Okugawa Y; Saigusa S; Ide S; Fujikawa H; Hiro J; Yasuda H; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Oncology; 2019; 96(2):70-78. PubMed ID: 30227430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life during postoperative chemoradiotherapy with oral uracil-tegafur and leucovorin in rectal cancer patients.
    Ozgen Z; Ozden S; Dane F; Atasoy BM; Akgun Z; Yumuk PF
    Hepatogastroenterology; 2013 May; 60(123):533-7. PubMed ID: 23159353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
    Tomono A; Yamashita K; Kanemitsu K; Sumi Y; Yamamoto M; Kanaji S; Imanishi T; Nakamura T; Suzuki S; Tanaka K; Kakeji Y
    Int J Clin Oncol; 2016 Apr; 21(2):344-349. PubMed ID: 26338272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.
    Kitayama J; Yasuda K; Kawai K; Sunami E; Nagawa H
    Radiat Oncol; 2010 Jun; 5():47. PubMed ID: 20525293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.
    Cellier P; Leduc B; Martin L; Vié B; Chevelle C; Vendrely V; Salemkour A; Carrie C; Calais G; Burtin P; Campion L; Boisdron-Celle M; Morel A; Berger V; Gamelin E
    BMC Cancer; 2011 Mar; 11():98. PubMed ID: 21410976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.